Temporal Changes in Fibrinolysis following Injury.


Journal

Seminars in thrombosis and hemostasis
ISSN: 1098-9064
Titre abrégé: Semin Thromb Hemost
Pays: United States
ID NLM: 0431155

Informations de publication

Date de publication:
Mar 2020
Historique:
entrez: 12 3 2020
pubmed: 12 3 2020
medline: 21 10 2020
Statut: ppublish

Résumé

Trauma patients present to the emergency department with a spectrum of fibrinolytic activity. This wide variance in fibrinolysis activity is a complex multifactorial process impacted by the degree of hemorrhagic shock and the amount of tissue injury the individual sustains. The fibrinolytic activity of the trauma patient at presentation to the hospital has prognostic and therapeutic implications. Those patients with high fibrinolytic activity (hyperfibrinolysis) are at risk of mortality from hemorrhage, whereas those patients with low fibrinolytic activity (shutdown or hypofibrinolysis) are at an increased risk of delayed mortality from traumatic brain injury or organ failure. These phenotypes of fibrinolysis acutely following injury change with resuscitation, and the majority of trauma patients will transition to a fibrinolytic resistant state several hours after injury. The mechanism for this near-global transition to this acquired fibrinolysis appears to be related to the generation of plasminogen activator inhibitor-1 in the liver. Those patients who do not recover from this fibrinolytic state 24 hours after injury have a poor prognosis. The purpose of this article is to review the different states of fibrinolytic activity following injury and how they change over time following resuscitation and in the intensive care unit.

Identifiants

pubmed: 32160644
doi: 10.1055/s-0039-1701016
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

189-198

Subventions

Organisme : T32-GM008315
ID : National Institute of General Medical Sciences (NIGMS)
Organisme : 1UM1HL120877
ID : National Heart Lung and Blood Institute (NHLBI)

Informations de copyright

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Déclaration de conflit d'intérêts

Both authors report nonfinancial support from Thrombo Therapeutics Inc., outside the submitted work. In addition, both authors have a patent tPA TEG assay pending.

Auteurs

Hunter B Moore (HB)

Division of Transplant Surgery, Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado.

Ernest E Moore (EE)

Division of Transplant Surgery, Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado.
Department of Surgery, Ernest E. Moore Shock and Trauma Center at Denver Health, Denver, Colorado.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH